Scaling Single Cell Protein from Lab to Pilot: A 2025 Milestone

In late 2025, our team reached a major milestone in our commercial journey: successfully scaling our single cell protein (SCP) production from laboratory scale to a 750 L pilot system. This achievement marks a critical step toward our goal of delivering low-cost, high-quality novel protein solutions for the animal feed industry.

The pilot-scale work was completed at CPI in England, leveraging their flexible bioprocessing infrastructure and world‑class technical expertise. This scale-up was made possible through the support of and strong collaboration with the University of Alberta and the Gates Foundation. Together, these partnerships enabled us to move rapidly from proof-of-concept to a meaningful demonstration of commercial relevance.

Biotechnology scale-up is rarely straightforward. Processes that perform reliably at bench scale often encounter unknowns when translated to larger volumes—ranging from mass transfer and mixing challenges to process control and reproducibility. The fact that we were able to take our lab-developed procedures and scale them to pilot volume within such a short timeframe is a testament to the discipline, technical rigor, and attention to detail demonstrated by our team. This success reflects countless hours of preparation, iteration, and expert insight from technical advisors.

Importantly, this pilot milestone is not an endpoint, but a launchpad. The data and material generated from this campaign will directly support additional work at the University of Alberta, including upcoming animal feed trials. These studies are a critical step toward demonstrating performance, safety, and consistency—key inputs for future regulatory approval applications and broader market adoption.

As global demand for sustainable protein continues to grow, scalable technologies like SCP will play an increasingly important role in strengthening feed supply chains while reducing environmental impact. We are proud of the progress made in 2025 and excited to build on this momentum as we advance toward commercialization.

We extend our sincere thanks to our partners, collaborators, and team members whose expertise and commitment made this milestone possible. The journey from lab to market is complex, but achievements like this reinforce our confidence in both our technology and our people.